Fixed‐duration glofitamab in patients with relapsed or refractory follicular lymphoma: Results from a Phase 1/2 study

Franck Morschhauser, Lorenzo Falchi, Carmelo Carlo‐Stella, Emmanuel Bachy, Michael Crump, Fritz Offner, Martin Hutchings, Anna Sureda, Krish Patel, Mark Hertzberg, Sirpa Leppa, Sonia Gonzalez de Villambrosia, Estefania Mulvihill, James Relf, Alessia Bottos, Vanessa Breton, Pauline Baumlin, Kathryn Humphrey, Linda Lundberg, Michael Dickinson
HemaSphere · Wiley · 2026-11-17 · DOI: 10.1002/hem3.70531

Abstract

Abstract More effective options are needed to personalize treatment for relapsed/refractory (R/R) follicular lymphoma (FL) by balancing efficacy, safety, and accessibility. We report efficacy and safety of glofitamab, a CD20xCD3 T‐cell engaging bispecific antibody, from a Phase 1/2 study in patients with R/R FL after ≥2 prior therapies. Overall, 61 patients were enrolled at the recommended Phase 2 dose of glofitamab (target dose, 30 mg). The overall response rate was 85.2% (95% confidence interval [CI] 73.8–93.0), and complete response (CR) rate was 77.0% (95% CI 64.5–86.9). After a median follow‐up of 29.3 months, the median duration of CR was 40.2 months (95% CI 20.0–not estimable [NE]). Median progression‐free survival was 21.4 months (95% CI 11.4–NE) and the 24‐month progression‐free survival rate was 49.0%. The most common adverse event was cytokine release syndrome (62.3%; all Grade ≤2). Immune effector cell‐associated neurotoxicity syndrome rates were low (6.5%; Grade ≤2, 4.9%; Grade 3, 1.6%). Patients had high rates of undetectable minimal residual disease at their first tumor assessment (Cycle 3) (76.3%), which lasted beyond the end‐of‐treatment (EOT). Immuno‐recovery occurred 12–18 months after EOT in patients with ongoing remission, and T‐cell count was not impacted by glofitamab treatment. Fixed‐duration glofitamab monotherapy induces durable responses with manageable safety. Glofitamab represents an accessible off‐the‐shelf therapy for patients with R/R FL, including those with high‐risk disease, and an important combination partner for the treatment of R/R FL. ClinicalTrials.gov identifier: NCT03075696.

Read at publisher →

Similar articles